{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"9.3","value":"4.8"},{"groupId":"OG001","lowerLimit":"3.9","upperLimit":"11.3","value":"6.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"description":"Time to progression is defined from the first day of therapy until documentation of progressive disease. Progressive disease (PD) is at least a 20% increase in the sum of the target lesions, or the appearance of one or more new lesions. Lymph node disease was assessed bi-dimensionally using the International Working Group (IWG) criteria. Bone marrow involvement, as recommended by IWG criteria, and presence of circulating malignant T-cells ascertained by flow cytometry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\\^2 and at 17.5 mg/m\\^2 on days 1, 8, and 15 of a 28 day cycle.","id":"OG000","title":"Peripheral T-cell Lymphoma (PTCL)"},{"description":"Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\\^2 and at 17.5 mg/m\\^2 on days 1, 8, and 15 of a 28 day cycle.","id":"OG001","title":"Cutaneous T-cell Lymphoma (CTCL)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Until disease progression, or 30 days following off study date","title":"Time to Progression","type":"SECONDARY","unitOfMeasure":"Months"}